Review article · 2019 · Open access

Diagnosis of Alzheimer’s disease utilizing amyloid and tau as fluid biomarkers

Jinny Claire Lee, Soo‐Jeong Kim, Seungpyo Hong, Young Soo Kim

Experimental & Molecular Medicine, 51(5), 1–10 · Published 1 May 2019 · DOI 10.1038/s12276-019-0250-2

Open PDFView at the publisherCite this paper

In brief

“Diagnosis of Alzheimer’s disease utilizing amyloid and tau as fluid biomarkers” is a 2019 review article by Jinny Claire Lee and 3 co-authors, published in Experimental & Molecular Medicine. OpenAlex counts 297 citations as of 19 November 2026, which puts it in the top 2% of works published in 2019 by citations. It is open access under a CC BY licence: the full text is free to read at Experimental & Molecular Medicine.

Citations
297
Most cited in
2022 (51)
Field-weighted impact
4.71
References
94
Authors
4

Abstract

Current technological advancements in clinical and research settings have permitted a more intensive and comprehensive understanding of Alzheimer’s disease (AD). This development in knowledge regarding AD pathogenesis has been implemented to produce disease-modifying drugs. The potential for accessible and effective therapeutic methods has generated a need for detecting this neurodegenerative disorder during early stages of progression because such remedial effects are more profound when implemented during the initial, prolonged prodromal stages of pathogenesis. The aggregation of amyloid-β (Aβ) and tau isoforms are characteristic of AD; thus, they are considered core candidate biomarkers. However, research attempting to establish the reliability of Aβ and tau as biomarkers has culminated in an amalgamation of contradictory results and theories regarding the biomarker concentrations necessary for an accurate diagnosis. In this review, we consider the capabilities and limitations of fluid biomarkers collected from cerebrospinal fluid, blood, and oral, ocular, and olfactory secretions as diagnostic tools for AD, along with the impact of the integration of these biomarkers in clinical settings. Furthermore, the evolution of diagnostic criteria and novel research findings are discussed. This review is a summary and reflection of the ongoing concerted efforts to establish fluid biomarkers as a diagnostic tool and implement them in diagnostic procedures. Markers from body fluids could help clinicians diagnose Alzheimer’s disease before cognitive decline appears. After numerous setbacks in treating advanced Alzheimer’s, researchers are eager to identify biological indicators that facilitate earlier disease detection and interception. A review by YoungSoo Kim and colleagues at Yonsei University in South Korea, explores the promise of ‘fluid biomarkers,’ which enables diagnosis using cerebrospinal fluid (CSF), blood, oral, ocular, and olfactory fluid samples. Shifts in CSF levels of amyloid beta and tau, two proteins central to Alzheimer’s pathology, can reliably monitor at-risk individuals. Although CSF collection is unpleasant for patients, it remains more promising than blood, where current data for candidate fluid biomarkers are relatively inconclusive. In this review, investigations to discover safer, cheaper, and more reliable diagnostic tools to shift treatment from alleviation to prevention are introduced.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Lee, J. C., Kim, S., Hong, S., & Kim, Y. S. (2019). Diagnosis of Alzheimer’s disease utilizing amyloid and tau as fluid biomarkers. Experimental & Molecular Medicine, 51(5), 1–10. https://doi.org/10.1038/s12276-019-0250-2

MLA 9

Lee, Jinny Claire, et al. “Diagnosis of Alzheimer’s disease utilizing amyloid and tau as fluid biomarkers.” Experimental & Molecular Medicine, vol. 51, no. 5, 2019, pp. 1–10. https://doi.org/10.1038/s12276-019-0250-2.

Chicago

Lee, Jinny Claire, Soo‐Jeong Kim, Seungpyo Hong, and Young Soo Kim. 2019. “Diagnosis of Alzheimer’s disease utilizing amyloid and tau as fluid biomarkers.” Experimental & Molecular Medicine 51 (5): 1–10. https://doi.org/10.1038/s12276-019-0250-2.

Harvard

Lee, J. C. et al. (2019) ‘Diagnosis of Alzheimer’s disease utilizing amyloid and tau as fluid biomarkers’, Experimental & Molecular Medicine, 51(5), pp. 1–10. doi:10.1038/s12276-019-0250-2.

IEEE

J. C. Lee, S. Kim, S. Hong, and Y. S. Kim, “Diagnosis of Alzheimer’s disease utilizing amyloid and tau as fluid biomarkers,” Experimental & Molecular Medicine, vol. 51, no. 5, pp. 1–10, 2019, doi: 10.1038/s12276-019-0250-2.

BibTeX

@article{lee2019diagnosis,
  title     = {{Diagnosis of Alzheimer’s disease utilizing amyloid and tau as fluid biomarkers}},
  author    = {Lee, Jinny Claire and Kim, Soo‐Jeong and Hong, Seungpyo and Kim, Young Soo},
  journal   = {Experimental \& Molecular Medicine},
  year      = {2019},
  volume    = {51},
  number    = {5},
  pages     = {1--10},
  doi       = {10.1038/s12276-019-0250-2},
  url       = {https://doi.org/10.1038/s12276-019-0250-2}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Citations by year

YearCitationsShare of the best year
20191010
20203939
20214646
20225151
20235151
20244949
20253131
20262020

Its field-weighted citation impact is 4.71: it has been cited 4.71 times as often as the average work of the same field, type and year (1.00 is the world average).

Topic and keywords

Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research

  • Alzheimer's disease
  • amyloid-beta
  • tau protein
  • fluid biomarkers
  • cerebrospinal fluid
  • blood biomarkers
  • early diagnosis
  • diagnostic criteria

Work with this paper

Most-cited papers in Medicine

All highly cited Medicine papers

Questions about this paper

How do I cite this paper in APA style?

Lee, J. C., Kim, S., Hong, S., & Kim, Y. S. (2019). Diagnosis of Alzheimer’s disease utilizing amyloid and tau as fluid biomarkers. Experimental & Molecular Medicine, 51(5), 1–10. https://doi.org/10.1038/s12276-019-0250-2

How many times has this paper been cited?

297 times, according to OpenAlex on 19 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at Experimental & Molecular Medicine: sign in and open the PDF from this page.

Who wrote this paper?

Jinny Claire Lee, Soo‐Jeong Kim, Seungpyo Hong, Young Soo Kim.

What is the DOI of this paper?

10.1038/s12276-019-0250-2, permanently at https://doi.org/10.1038/s12276-019-0250-2. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 19 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.